Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Osteoporosis highly prevalent in COPD patients

08 Aug 2019

The prevalence of osteoporosis among patients with chronic obstructive pulmonary disease (COPD) appears to be high and similar in many countries, according to the results of a meta-analysis.

Researchers searched multiple online databases for studies reporting the prevalence and risk factors for osteoporosis in COPD. Two reviewers conducted eligibility screening, data extraction and quality assessment of the retrieved articles.

The meta-analysis included 58 studies. Pooled global prevalence of osteoporosis in COPD was 38 percent (95 percent CI, 34–43). The likelihood of having the bone disease increased by more than twofold in the presence of COPD (odds ratio [OR], 2.83).

Additional significant risk factors for osteoporosis in COPD patients were low body mass index (<18.5 kg/m2; OR, 4.26) and the presence of sarcopenia (OR, 3.65).

The present data suggest that COPD patients should be regularly screened for osteoporosis and contributing risk factors, the researchers said.

Osteoporosis is one of the major systemic comorbidities of COPD and is associated with significant morbidity. Factors implicated in the pathogenesis of the bone disease include systemic inflammatory, physical inactivity, body composition changes, tobacco exposure, corticosteroids use, hypogonadism, anaemia, COPD exacerbation and hypoxia. [Int J Chron Obstruct Pulmon Dis 2016;11:637-648; Clin Med Insights Circ Respir Pulm Med 2015;9:5-21]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.